BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 26969325)

  • 1. No correlation between NF1 mutation position and risk of optic pathway glioma in 77 unrelated NF1 patients.
    Hutter S; Piro RM; Waszak SM; Kehrer-Sawatzki H; Friedrich RE; Lassaletta A; Witt O; Korbel JO; Lichter P; Schuhmann MU; Pfister SM; Tabori U; Mautner VF; Jones DTW
    Hum Genet; 2016 May; 135(5):469-475. PubMed ID: 26969325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A molecular analysis of individuals with neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and an assessment of genotype-phenotype correlations.
    Sharif S; Upadhyaya M; Ferner R; Majounie E; Shenton A; Baser M; Thakker N; Evans DG
    J Med Genet; 2011 Apr; 48(4):256-60. PubMed ID: 21278392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genotype-phenotype associations in neurofibromatosis type 1 (NF1): an increased risk of tumor complications in patients with NF1 splice-site mutations?
    Alkindy A; Chuzhanova N; Kini U; Cooper DN; Upadhyaya M
    Hum Genomics; 2012 Aug; 6(1):12. PubMed ID: 23244495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NF1 germline mutation differentially dictates optic glioma formation and growth in neurofibromatosis-1.
    Toonen JA; Anastasaki C; Smithson LJ; Gianino SM; Li K; Kesterson RA; Gutmann DH
    Hum Mol Genet; 2016 May; 25(9):1703-13. PubMed ID: 26908603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optic glioma and precocious puberty in a girl with neurofibromatosis type 1 carrying an R681X mutation of NF1: case report and review of the literature.
    Kocova M; Kochova E; Sukarova-Angelovska E
    BMC Endocr Disord; 2015 Dec; 15():82. PubMed ID: 26666878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical signs and genetic evaluation of patients with neurofibromatosis type 1 with and without optic pathway gliomas in a center in Turkey.
    Sharafi P; Varan A; Ersoy-Evans S; Ayter S
    Childs Nerv Syst; 2024 Feb; 40(2):511-515. PubMed ID: 37401974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clustering of mutations in the 5' tertile of the NF1 gene in Slovakia patients with optic pathway glioma.
    Bolcekova A; Nemethova M; Zatkova A; Hlinkova K; Pozgayova S; Hlavata A; Kadasi L; Durovcikova D; Gerinec A; Husakova K; Pavlovicova Z; Holobrada M; Kovacs L; Ilencikova D
    Neoplasma; 2013; 60(6):655-65. PubMed ID: 23906300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Overview of Optic Pathway Glioma With Neurofibromatosis Type 1: Pathogenesis, Risk Factors, and Therapeutic Strategies.
    Chen Y; Yu J; Ge S; Jia R; Song X; Wang Y; Fan X
    Invest Ophthalmol Vis Sci; 2024 Jun; 65(6):8. PubMed ID: 38837168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NF1 mutation drives neuronal activity-dependent initiation of optic glioma.
    Pan Y; Hysinger JD; Barron T; Schindler NF; Cobb O; Guo X; Yalçın B; Anastasaki C; Mulinyawe SB; Ponnuswami A; Scheaffer S; Ma Y; Chang KC; Xia X; Toonen JA; Lennon JJ; Gibson EM; Huguenard JR; Liau LM; Goldberg JL; Monje M; Gutmann DH
    Nature; 2021 Jun; 594(7862):277-282. PubMed ID: 34040258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy.
    Sharif S; Ferner R; Birch JM; Gillespie JE; Gattamaneni HR; Baser ME; Evans DG
    J Clin Oncol; 2006 Jun; 24(16):2570-5. PubMed ID: 16735710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844-848.
    Koczkowska M; Chen Y; Callens T; Gomes A; Sharp A; Johnson S; Hsiao MC; Chen Z; Balasubramanian M; Barnett CP; Becker TA; Ben-Shachar S; Bertola DR; Blakeley JO; Burkitt-Wright EMM; Callaway A; Crenshaw M; Cunha KS; Cunningham M; D'Agostino MD; Dahan K; De Luca A; Destrée A; Dhamija R; Eoli M; Evans DGR; Galvin-Parton P; George-Abraham JK; Gripp KW; Guevara-Campos J; Hanchard NA; Hernández-Chico C; Immken L; Janssens S; Jones KJ; Keena BA; Kochhar A; Liebelt J; Martir-Negron A; Mahoney MJ; Maystadt I; McDougall C; McEntagart M; Mendelsohn N; Miller DT; Mortier G; Morton J; Pappas J; Plotkin SR; Pond D; Rosenbaum K; Rubin K; Russell L; Rutledge LS; Saletti V; Schonberg R; Schreiber A; Seidel M; Siqveland E; Stockton DW; Trevisson E; Ullrich NJ; Upadhyaya M; van Minkelen R; Verhelst H; Wallace MR; Yap YS; Zackai E; Zonana J; Zurcher V; Claes K; Martin Y; Korf BR; Legius E; Messiaen LM
    Am J Hum Genet; 2018 Jan; 102(1):69-87. PubMed ID: 29290338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
    Gottfried ON; Viskochil DH; Couldwell WT
    Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1.
    Freret ME; Gutmann DH
    J Neurosci Res; 2019 Jan; 97(1):45-56. PubMed ID: 29704429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-occurrence of neurofibromatosis type 1 and optic nerve gliomas with autosomal dominant polycystic kidney disease type 2.
    Peces R; Mena R; Martín Y; Hernández C; Peces C; Tellería D; Cuesta E; Selgas R; Lapunzina P; Nevado J
    Mol Genet Genomic Med; 2020 Aug; 8(8):e1321. PubMed ID: 32533764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments.
    Amato A; Imbimbo BP; Falsini B
    Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5636-5653. PubMed ID: 37401302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics and spectrum of NF1 mutations in 12 unrelated Chinese families with neurofibromatosis type 1.
    Mao B; Chen S; Chen X; Yu X; Zhai X; Yang T; Li L; Wang Z; Zhao X; Zhang X
    BMC Med Genet; 2018 Jun; 19(1):101. PubMed ID: 29914388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visual acuity of children treated with chemotherapy for optic pathway gliomas.
    Kalin-Hajdu E; Décarie JC; Marzouki M; Carret AS; Ospina LH
    Pediatr Blood Cancer; 2014 Feb; 61(2):223-7. PubMed ID: 23956233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients.
    Segal L; Darvish-Zargar M; Dilenge ME; Ortenberg J; Polomeno RC
    J AAPOS; 2010 Apr; 14(2):155-8. PubMed ID: 20451859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parent-of-origin in individuals with familial neurofibromatosis type 1 and optic pathway gliomas.
    Johnson KJ; Fisher MJ; Listernick RL; North KN; Schorry EK; Viskochil D; Weinstein M; Rubin JB; Gutmann DH
    Fam Cancer; 2012 Dec; 11(4):653-6. PubMed ID: 22829012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain gliomas, hydrocephalus and idiopathic aqueduct stenosis in children with neurofibromatosis type 1.
    Glombova M; Petrak B; Lisy J; Zamecnik J; Sumerauer D; Liby P
    Brain Dev; 2019 Sep; 41(8):678-690. PubMed ID: 31000370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.